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A B S T R A C T   
Objectives: Lateral geniculate nucleus (LGN) volume is reduced after optic neuritis (ON) in neuromyelitis optica 
spectrum disorders (NMOSD). We aimed at a longitudinal assessment of LGN volume in NMOSD. 
Methods: Twenty-nine patients with aquaporin 4-IgG seropositive NMOSD (age: 47.8 ± 14.6 years (y), female: n 
= 27, history of ON (NMO-ON): n = 17, median time since ON: 3[1.2–12.1]y) and 18 healthy controls (HC; age: 
39.3 ± 15.8y; female: n = 13) were included. Median follow-up was 4.1[1.1–4.7]y for patients and 1.7[0.9–3.2]y 
for HC. LGN volume was measured using a multi-atlas-based approach of automated segmentation on 3 Tesla 
magnetic resonance images. Retinal optical coherence tomography and probabilistic tractography of the optic 
radiations (OR) were also performed. 
Results: At baseline, NMO-ON patients had lower LGN volumes (395.4 ± 48.9 mm3) than patients without ON 
(NMO-NON: 450.7 ± 55.6 mm3; p = 0.049) and HC (444.5 ± 61.5 mm3, p = 0.025). LGN volume was associated 
with retinal neuroaxonal loss and microstructural OR damage. Longitudinally, there was no change in LGN 
volumes in the absence of ON, neither in all patients (B = − 0.6, SE = 1.4, p = 0.670), nor in NMO-ON (B = − 0.8, 
SE = 1.6, p = 0.617) and NMO-NON (B = 1.7, SE = 3.5, p = 0.650). However, in four patients with new ON 
Abbreviations: AD, axial diffusivity; AQP4, aquaporin-4; cR2, conditional R2; DTI, diffusion tensor imaging; EDSS, expanded disability status scale; FA, fractional 
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optic neuritis; NMOSD, neuromyelitis optica spectrum disorders; ON, optic neuritis; OR, optic radiations; pRNFL, peripapillary retinal nerve fiber layer; RD, radial 
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during follow-up, LGN volume was reduced at last visit (median time since ON: 2.6 [1.8–3.9] y) compared to the 
measurement before ON (352 ± 52.7 vs. 371.1 ± 55.9 mm3; t = − 3.6, p = 0.036). 
Conclusion: Although LGN volume is reduced after ON in NMOSD, this volume loss is not progressive over longer 
follow-up or independent of ON. Thus, our findings -at least in this relatively small cohort- do not support occult 
neurodegeneration of the afferent visual pathway in NMOSD.   
1. Introduction 
Neuromyelitis optica spectrum disorders (NMOSD) are relapsing 
inflammatory disorders of the central nervous system (CNS) (Wing-
erchuk et al., 2015). Most patients with NMOSD (60–80%) have 
detectable serum antibodies binding to the water channel aquaporin-4 
(AQP4–immunoglobulin G (IgG) seropositive NMOSD) (Lennon et al., 
2004; Paul et al., 2007). 
The afferent visual pathway is frequently affected in AQP4-IgG 
seropositive NMOSD, with optic neuritis (ON) being a typical clinical 
manifestation (Wingerchuk et al., 2015; Jarius et al., 2014; Borisow 
et al., 2018). The well-defined structure of the visual pathway, with its 
distinct nodes (retinal ganglion cells, optic nerve, lateral geniculate 
nucleus (LGN), optic radiation (OR) and primary visual cortex) makes it 
a suitable model to study pathological mechanisms of the disease (Pfu-
eller and Paul, 2011; Oertel et al., 2018). 
Previous studies in NMOSD assessed damage in the LGN and the OR 
via magnetic resonance imaging (MRI). It was shown, that patients with 
previous optic neuritis (NMO-ON) have smaller LGN volumes compared 
to patients without ON (NMO-NON) and to healthy controls (HC) 
(Papadopoulou et al., 2019; Tian et al., 2018). Moreover, microstruc-
tural changes in the OR of NMO-ON patients were described, using 
diffusion tensor and myelin water imaging (Tian et al., 2018; Pichiec-
chio et al., 2012; Manogaran et al., 2016; Oertel et al., 2017). These 
observations suggest anterograde transsynaptic degeneration along the 
afferent visual pathway of NMO-ON patients, resulting in LGN and OR 
damage (Papadopoulou et al., 2019; Tian et al., 2018; Pichiecchio et al., 
2012; Manogaran et al., 2016; Oertel et al., 2017). Interestingly, OR 
changes were also observed in NMO-NON patients compared to HC 
(Tian et al., 2018; Oertel et al., 2017). However, these previous findings 
derived from cross-sectional studies. 
Our objective was to assess the longitudinal course of LGN volume in 
AQP4-IgG seropositive NMOSD. We aimed at evaluating whether 
ongoing LGN volume loss occurs during the disease course or whether 
loss is solely associated to previous ON. Moreover, we aimed at quan-
tifying the course of LGN volume change in patients presenting with new 
ON episodes during follow-up. 
2. Materials and methods 
2.1. Study participants 
We screened 78 patients with NMOSD from an ongoing observational 
cohort study at the NeuroCure Clinical Research Center at Charité – 
Universitätsmedizin Berlin (recruited from May 2013 to January 2018). 
Inclusion criteria were: i) age ≥ 18 years, ii) AQP4-IgG seropositive 
NMOSD, according to the 2015 International Consensus Diagnostic 
Criteria (Wingerchuk et al., 2015) and iii) at least one clinical and MRI 
follow-up visit. AQP4-IgG seropositivity was determined by a cell-based 
assay (Euroimmun, Lübeck, Germany) (Jarius et al., 2014). Patients that 
were AQP4-IgG seronegative (n = 25), or had incomplete clinical data, 
or unknown AQP4-IgG-status (n = 10), or no follow-up MRI data (n =
11) were excluded. In order to avoid an influence of acute inflammatory 
activity on the analysis, we excluded visits of patients with an attack 
within six months before ths visit (n = 3 visits of 3 patients as well as 3 
patients totally excluded, due to attacks within six months prior to every 
visit), except if the attack was a new ON during follow-up. Altogether, 
29 patients were included in the analysis. It must be noted that visits of 
these patients (one visit of each) had been previously included in a cross- 
sectional analysis of the LGN in NMOSD (Papadopoulou et al., 2019). 
At every visit, patients underwent a comprehensive neurological 
examination to assess the Expanded Disability Status Scale (EDSS), 
Fig. 1. LGN segmentation by MAGeT. Legend: This 
figure is a representative lateral geniculate nucleus 
(LGN) segmentation in a control subject, as per-
formed by the MAGeT brain algorithm (Chakravarty 
et al., 2013, 2006). The LGN is shown in red at: A) 
axial, B) coronal and C) sagittal view, on a 3D T1- 
weighted magnetization prepared rapid acquisition 
gradient echo (MPRAGE) sequence. (For interpreta-
tion of the references to colour in this figure legend, 
the reader is referred to the web version of this 
article.)   
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according to the Neurostatus definitions (Kappos et al., 2015). Attack 
history including ON was recorded using clinical criteria (Petzold et al., 
2014). 
Median follow-up for the patients was 4.1 years (range: 1.1–4.7); in 
particular patients with previous ON (NMO-ON) had a median follow-up 
of 4.2 years (range 1.1–4.7) and patients without previous ON (NMO- 
NON) had a median follow-up of 3.1 years (range 1.1–4.5). 
Longitudinal data from 18 HC with age ≥ 18 years, at least one MRI 
follow-up, without a history of neurological or opthalmological diseases 
were also included. HC were chosen from the institute’s research data-
base, to be as well matched as possible with the patients’ age and sex. 
Twelve of the HC had been also included in our previous cross-sectional 
analysis of the LGN in NMOSD (Papadopoulou et al., 2019). Median 
follow-up for the HC was 1.7 years (range: 0.9–3.2). 
This study was approved by the local ethics committee (Ethikkom-
mission der Charité – Universitätsmedizin Berlin; EA1/041/14 and EA1/ 
163/12) and conducted in accordance with the declaration of Helsinki in 
its currently applicable version. All participants gave written informed 
consent before inclusion in the study. 
2.2. Magnetic resonance imaging (MRI) 
3 Tesla MRI was performed at every visit for all participants 
(MAGNETOM Trio Tim, Siemens, Erlangen, Germany). Details regarding 
the MRI protocol are given as Supplementary material. 
2.3. Measurement of LGN volume 
LGN volumes were measured at all timepoints using the Multiple 
Automatically Generated Templates (MAGeT) brain algorithm (Chak-
ravarty et al., 2013) on isotropic 3D T1-weighted magnetization pre-
pared rapid acquisition gradient echo (MPRAGE) images. MAGeT uses 
an atlas derived from manually segmented serial histological data, 
including delineation of the thalamic nuclei. It first customizes the atlas 
to a subset of participants, representative of the study population, using 
nonlinear registration and uses this newly segmented subset as a tem-
plate library for the remaining participants. This has the advantage of 
correcting for the neuroanatomical variability of the study population 
(Chakravarty et al., 2013). Details regarding the representative subset of 
the present study are given as Supplementary material. 
Segmentation results were visually inspected by one experienced 
rater (S.M.), who was blinded to the clinical data. No subjects had to be 
excluded. All volumes were normalised using the SIENAX V-scaling 
factor for head-size (Smith et al., 2002). In the analysis, we used the sum 
of the right and left LGN, defined as “total LGN volume”. 
An example of the LGN as segmented by MAGeT can be seen in Fig. 1. 
2.4. Assessment of the OR microstructure 
Diffusion tensor imaging (DTI)-based probabilistic tractography 
were used to assess the OR microstructure. The methodological details 
are given as Supplementary material. Tract profiles of weighted mean 
values of fractional anisotropy (FA), mean diffusivity (MD), radial 
diffusivity (RD), and axial diffusivity (AD) at 50 equally spaced positions 
of the OR were computed at all timepoints. The mean values of these 50 
positions were used in the analysis. 
Eight patients and four HC (total of 12 participants) did not have 
DTI-data at baseline (n = 9 due to failure of tract generation and n = 3 
due to not available DTI-sequence). 
2.5. Retinal optical coherence tomography (OCT) 
Retinal imaging was performed for all participants, using a Heidel-
berg Engineering Spectralis spectral domain OCT (Heidelberg Engi-
neering, Heidelberg, Germany). We report the OCT acquisition settings, 
scanning protocol and details regarding excluded scans as 
Supplementary material. 
The mean peripapillary retinal nerve fiber layer (pRNFL) thickness 
and the mean combined ganglion cell and inner plexiform layer (GCIPL) 
thickness at baseline were used. The longitudinal OCT data of this cohort 
were previously published by our group as part of a multicenter study 
(Oertel et al., 2018). 
2.6. Statistical analysis 
Differences at baseline characteristics between patients and HC were 
investigated using t-test (age), Fisher’s exact test (sex- and handedness- 
distribution) and analysis of covariance (ANCOVA model Type III with 
adjustment for age and sex to compare baseline OCT- and DTI-measures 
among: NMO-ON, NMO-NON and HC). 
Total LGN volume at baseline was also compared among these three 
groups using ANCOVA. Moreover, the associations between total LGN 
volume and other measures of the visual pathway (pRNFL, GCIPL, OR- 
FA, OR-MD, OR-RD and OR-AD; in all cases mean of both eyes/hemi-
spheres) were examined in linear regression models with adjustment for 
age and sex. 
For the longitudinal analysis, linear mixed effect models (LMM) were 
used. To study the course of total LGN volume over time in the different 
groups (NMOSD, NMO-ON, NMO-NON, HC), we used a LMM with fixed 
effects: time since baseline, age and sex and random effects based on 
subject and visit (total LGN volume ~ time since baseline + age + sex +
(1 |time since baseline|subject)). For the NMO-ON subgroup we also 
performed two LMM using time since first- and last ON episode, instead 
of time since baseline. 
To study group-differences in the course of total LGN volume, we 
used a LMM with fixed effects: the interaction between time since 
baseline and group, as well as age and sex, and random effects based on 
subject and visit (total LGN volume ~ time since baseline × group + age 
+ sex + (1 |time since baseline|subject)). From all models, patients with 
Table 1 
Baseline characteristics of the study participants.  
Baseline characteristics AQP4-IgG seropositive 
NMOSD (n = 29) 
HC (n =
18) 
Age, years (mean ± SD) 47.8 ± 14.6 39.3 ± 15.8 
Sex: female/male (female %) 27/2 (93.1%) 13/5 
(72.2%) 
Handedness: right/left (righthanded 
%) 
26/3 (89.7%) 18/ 
0 (100%) 
Race: Caucasian/African/Asian 27/1/1 18/0/0 
Disease duration, years: median 
(range) 
4.6 (0.5–28.0) – 
Follow-up time, years: median 
(range) 
4.1 (1.1–4.7) 1.7 
(0.9–3.2) 
EDSS: median (range) 3.5 (1–6.5) – 
Patients on immunosuppressive 
treatment: n (%) 
28 (96.6%)* – 
Total number of previous attacks: 
median (range) 
3 (1–21) – 
Patients with myelitis: n (%) 27 (93.1%) – 
Patients with ON: n (%) 17 (58.6%) – 
Number of ON episodes per patient: 
median (range) 
1 (0–7) – 
Time since fist ON episode, years: 
median (range) 
4.6 (1.8–28.0) – 
Time since last ON episode, years: 
median (range) 
3.0 (1.2–12.1) – 
Patients and HC showed no significant difference regarding mean age (t = − 1.8, 
p = 0.076), sex (OR = 5.0, p = 0.089) or handedness (OR = 0, p = 0.276). 
Abbreviations: AQP4-IgG = Aquaporin-4 immunoglobulin-G, EDSS = Expanded 
Disability Status Scale, HC = healthy controls, NMOSD = neuromyelitis optica 
spectrum disorders, ON = optic neuritis, SD = standard deviation. 
* The only untreated patient at baseline had previous treatment with cyclo-
phoshamid until 4 years before study-baseline but did not receive any perma-
nent immunomodulatory/immunosuppressive treatment during the study. 
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new ON episodes during follow-up were excluded. 
To analyse the course of total LGN volume change for patients with 
new ON during follow-up, we used a paired t-test, since the number of 
these patients was too low to perform LMM (n = 4). We compared total 
LGN volume between: i) V0 (last visit before new ON) and V1 (first visit 
after new ON), and ii) V0 and Vlast (last available visit). As a control- 
analysis, we performed the same paired t-tests in four patients without 
new ON during follow-up, who were matched to the patients with new 
ON regarding relevant characteristics (such as age, sex, race, prior ON, 
etc.). 
For all models, statistical significance was set at p < 0.05. All sta-
tistical analysis was performed using R version 3.4.3 (R Core Team, 
2017) with packages: pastecs, compute.es, car, effects, multcomp, stats, 
WRSS, lme4, lmerTest, MuMIn, Matrix and ggplot2. 
2.7. Data availability statement 
All fully anonymised data that were used in the analysis can be 
shared upon reasonable request from qualified investigators. 
3. Results 
3.1. Baseline characteristics of the study participants 
The baseline demographics and clinical characteristics of the study 
participants are summarized in Table 1. 
The imaging characteristics (OCT- and DTI-measures) of NMO-ON, 
NMO-NON patients and HC at baseline are summarized in Table 2. 
The OCT-measures showed significant group differences at baseline: 
between NMO-ON and NMO-NON, as well as between NMO-ON and HC 
(Table 2). In contrast, there were no baseline group-differences 
regarding the DTI-measures (Table 2). Since we suspected that this 
might be attributed to reduced power due to many subjects without 
baseline DTI data (n = 12), we also performed a group comparison of the 
DTI measures at the last follow-up visit, where only 3 subjects had no 
DTI data (using again the same ANCOVA models as at baseline). At this 
time-point, we indeed found significant group-differences in OR-FA, OR- 
MD and OR-RD (Table 2). 
3.2. LGN volume at baseline 
At baseline, mean total LGN volume was 444.5 ± 61.5 mm3 in HC, 
450.7 ± 55.6 mm3 in NMO-NON patients and 395.4 ± 48.9 mm3 in 
NMO-ON patients. In an analysis of covariance with adjustment for age 
and sex, total LGN volume was associated with group (HC vs. NMO-NON 
vs. NMO-ON; F = 4.89, p = 0.012). 
In detail, NMO-ON patients had lower volumes compared to HC (B =
− 53.2, SE = 19.6, 95% CI: − 53.2 to − 100.8, t = − 2.7, p = 0.025) and to 
NMO-NON patients (B = − 53.0, SE = 21.7, 95% CI: − 53.0 to − 105.8, t 
= − 2.4, p = 0.049), while NMO-NON patients did not differ from HC (B 
= − 0.2, SE = 23.4, 95% CI: − 56.9 to 56.6, t = − 0.007, p > 0.99). 
Moreover, total LGN volume at baseline was associated with mea-
sures of neuroaxonal loss in the retina (mean pRNFL and GCIPL thick-
nesses) and of microstructural damage in the OR (mean OR-FA, OR-MD, 
OR-RD and OR-AD; Table 3 and Fig. 2). 
In a subgroup analysis, most associations remained in the NMO-ON 
patients (Table 3), while there were no associations in the NMO-NON 
subgroup and in HC (Table 3). 
Table 2 
Cross-sectional group-comparisons of OCT- and DTI-measures.   
NMO-ON NMO-NON HC ANCOVA NMO-ON vs. NMO-NON NMO-ON vs. HC NMO-NON vs. HC 
Mean pRNFL thickness at baseline, µm 72.3 ± 20.5 
(n = 15) 
98.5 ± 12.2 
(n = 12) 
95.6 ± 11.3 
(n = 17) 
F = 12.30 
p < 0.001 
B ¼ − 26.9 
(SE ¼ 6.4) 
p < 0.001 
B ¼ –23.3 
(SE ¼ 5.8) 
p < 0.001 
B = 3.6 
(SE = 6.8) 
p = 0.862 
Mean GCIPL thickness at baseline, µm 62.0 ± 10.3 
(n = 15) 
76.7 ± 5.1 
(n = 11) 
78.7 ± 7.1 
(n = 17) 
F = 18.29 
p < 0.001 
B ¼ − 15.4 
(SE ¼ 3.3) 
p < 0.001 
B ¼ − 16.3 
(SE ¼ 3.1) 
p < 0.001 
B = − 0.9 
(SE = 3.6) 
p = 0.965 
Mean OR-FA at baseline 0.484 ± 0.03 
(n = 11) 
0.505 ± 0.03 
(n = 10) 
0.510 ± 0.03 
(n = 14) 
F = 2.32 
p = 0.116 
B = − 0.03 
(SE = 0.01) 
p = 0.133 
B = − 0.02 
(SE = 0.01) 
p = 0.254 
B = 0.01 
(SE = 0.01) 
p = 0.887 
Mean OR-MD at baseline 0.941 ± 0.10 
(n = 11) 
0.90 ± 0.07 
(n = 10) 
0.955 ± 0.09 
(n = 14) 
F = 1.51 
p = 0.238 
B = 0.05 
(SE = 0.04) 
p = 0.463 
B = − 0.02 
(SE = 0.04) 
p = 0.814 
B = − 0.07 
(SE = 0.04) 
p = 0.214 
Mean OR-RD at baseline 0.688 ± 0.11 
(n = 11) 
0.635 ± 0.07 
(n = 10) 
0.685 ± 0.09 
(n = 14) 
F = 1.48 
p = 0.244 
B = 0.06 
(SE = 0.04) 
p = 0.335 
B = − 0.01 
(SE = 0.04) 
p = 0.972 
B = − 0.07 
(SE = 0.04) 
p = 0.260 
Mean OR-AD at baseline 1.447 ± 0.10 
(n = 11) 
1.418 ± 0.06 
(n = 10) 
1.494 ± 0.11 
(n = 14) 
F = 1.76 
p = 0.190 
B = 0.03 
(SE = 0.04) 
p = 0.781 
B = − 0.05 
(SE = 0.04) 
p = 0.415 
B = − 0.08 
(SE = 0.05) 
p = 0.181 
Mean OR-FA at last visit 0.468 ± 0.04 
(n = 17) 
0.507 ± 0.03 
(n = 11) 
0.514 ± 0.03 
(n = 16) 
F = 7.15 
p = 0.002 
B ¼ − 0.04 
(SE ¼ 0.01) 
p ¼ 0.014 
B ¼ − 0.04 
(SE ¼ 0.01) 
p ¼ 0.007 
B = − 0.0003 
(SE = 0.02) 
p > 0.999 
Mean OR-MD at last visit 1.022 ± 0.17 
(n = 17) 
0.888 ± 0.06 
(n = 11) 
0.940 ± 0.10 
(n = 16) 
F = 4.05 
p = 0.025 
B ¼ 0.12 
(SE ¼ 0.05) 
p ¼ 0.041 
B = 0.09 
(SE = 0.04) 
p = 0.104 
B = − 0.03 
(SE = 0.05) 
p = 0.860 
Mean OR-RD at last visit 0.771 ± 0.18 
(n = 17) 
0.627 ± 0.06 
(n = 11) 
0.670 ± 0.10 
(n = 16) 
F = 4.77 
p = 0.014 
B ¼ 0.13 
(SE ¼ 0.05) 
p ¼ 0.029 
B = 0.11 
(SE = 0.05) 
p = 0.058 
B = − 0.02 
(SE = 0.06) 
p = 0.903 
Mean OR-AD at last visit 1.524 ± 0.16 
(n = 17) 
1.410 ± 0.08 
(n = 11) 
1.479 ± 0.11 
(n = 16) 
F = 2.40 
p = 0.104 
B = 0.10 
(SE = 0.05) 
p = 0.111 
B = 0.06 
(SE = 0.04) 
p = 0.350 
B = − 0.04 
(SE = 0.05) 
p = 0.772 
For all measures the mean ± standard deviation is shown; they all represent the mean of both sides (for OCT-measures: both eyes and for DTI-measures: both cerebral 
hemispheres). Note that due to reduced number of participants with baseline DTI-data (n = 12 missing), we also performed the cross-sectional group comparisons at 
the last follow-up visit (only n = 3 missing). These results are shown below the baseline DTI- results (“at last visit”). Significant results are marked in bold. 
Abbreviations: AQP4-IgG = Aquaporin-4 immunoglobulin-G, DTI = diffusion-tensor imaging, GCIPL = ganglion cell-inner plexiform layer, HC = healthy controls, 
NMO-NON: patients without previous optic neuritis, NMO-ON = patients with previous optic neuritis, OCT = optical coherence tomography, ON = optic neuritis, OR- 
AD: axial diffusivity of the optic radiations, OR-FA: fractional anisotropy of the optic radiations, OR-MD = mean diffusivity of the optic radiations, OR-RD: radial 
diffusivity of the optic radiations, pRNFL = peripapillary retinal nerve layer 
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Table 3 
Associations between total LGN volume and measures of damage in the retina and the OR at baseline.  
Total LGN volume Mean pRNFL thickness Mean GCIPL thickness Mean OR-FA Mean OR-MD Mean OR-RD Mean OR-AD 
NMOSD B ¼ 1.9 
SE ¼ 0.5 
p < 0.001 
B ¼ 3.7 
SE ¼ 1.0 
p < 0.001 
B ¼ 1018.2 
SE ¼ 358.0 
p ¼ 0.011 
B ¼ − 455.1 
SE ¼ 121.5 
p ¼ 0.002 
B ¼ − 417.0 
SE ¼ 118.4 
p ¼ 0.003 
B ¼ − 468.7 
SE ¼ 125.8 
p ¼ 0.002 
NMO-ON B ¼ 1.9 
SE ¼ 0.6 
p ¼ 0.006 
B = 2.6 
SE = 1.4 
p = 0.086 
B = 762.6 
SE = 502.5 
p = 0.173 
B ¼ − 367.9 
SE ¼ 128.0 
p ¼ 0.024 
B ¼ − 328.7 
SE ¼ 134.3 
p ¼ 0.044 
B ¼ − 404.6 
SE ¼ 112.2 
p ¼ 0.009 
NMO-NON B = − 0.6 
SE = 1.4 
p = 0.657 
B = 2.1 
SE = 3.5 
p = 0.553 
B = 810.6 
SE = 587.5 
p = 0.210 
B = − 436.4 
SE = 268.7 
p = 0.148 
B = − 388.1 
SE = 254.2 
p = 0.171 
B = − 441.3 
SE = 279.4 
p = 0.158 
HC B = 1.2 
SE = 1.7 
p = 0.483 
B = 2.0 
SE = 3.1 
p = 0.538 
B = 1130.6 
SE = 771.8 
p = 0.171 
B = − 155.6 
SE = 205.4 
p = 0.465 
B = − 186.2 
SE = 217.7 
p = 0.411 
B = − 99.0 
SE = 174.9 
p = 0.583 
The different columns show the associations of total LGN volume with the different measures of damage in the retina (mean pRNFL and GCIPL thicknesses) and the OR 
(mean OR-FA, mean OR-MD, mean OR-RD, mean OR-AD) at baseline. The different rows represent the analysis in the entire patient group (NMOSD), the subgroup with 
previous ON (NMO-ON), the subgroup without previous ON (NMO-NON) and the healthy controls (HC). Significant associations are marked in bold. 
Abbreviations: AD = axial diffusivity, AQP4 = aquaporin 4, B = beta estimate of the linear mixed effect models, GCIPL: ganglion cell-inner plexiform layer, FA =
fractional anisotropy, LGN = lateral geniculate nucleus, MD = mean diffusivity, NMO-NON: patients without history of optic neuritis, NMO-ON: patients with positive 
history of optic neuritis, NMOSD = neuromyelitis optica spectrum disorders, pRNFL = peripapillary retinal nerve fiber layer, OR = optic radiation, RD = radial 
diffusivity, SE = standard error of the B. 
Fig. 2. Cross-sectional associations between total LGN volume and other measures of structural damage in the visual pathway. Legend: At baseline, total LGN 
volume of AQP4 IgG seropositive NMOSD patients was associated with the measures of neuroaxonal loss in the retina: A) mean pRNFL thickness, and B) mean GCIPL 
thickness, as well as with the measures of microstructural damage in the optic radiations: C) mean OR-FA, D) mean OR-MD, E) mean OR-RD and F) mean OR-AD. 
Abbreviations: AD = axial diffusivity, GCIPL: ganglion cell-inner plexiform layer, FA = fractional anisotropy, LGN = lateral geniculate nucleus, MD = mean 
diffusivity, pRNFL = peripapillary retinal nerve fiber layer, OR = optic radiation, RD = radial diffusivity, SE = standard error. 
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3.3. Longitudinal course of LGN volume 
3.3.1. Patients without new ON during follow-up 
After exclusion of four patients that showed new ON episodes during 
follow-up, we examined the longitudinal course of total LGN volume in 
the cohort. We found no change in total LGN volume over time, neither 
in all remaining patients (B = − 0.6, SE = 1.4, p = 0.670), nor in the 
NMO-ON (B = − 0.8, SE = 1.6, p = 0.617) and NMO-NON subgroups (B 
= 1.7, SE = 3.5, p = 0.650). In the NMO-ON subgroup the results did not 
change when evaluating the length of time since an ON attack rather 
than the duration since baseline in the analysis (results for time since 
first ON episode: B = 0.8, SE = 0.8, p = 0.425; results for time since last 
ON episode: B = 0.2, SE = 1.5, p = 0.910). It should be noted that in HC 
(shorter follow-up time compared to patients: median 1.7 years) there 
was also no significant total LGN volume change during this study (B =
− 3.8, SE = 3.6, p = 0.304). Moreover, there was no group effect on the 
course of total LGN volume change (Fig. 3). 
In line with the LGN-results, there was also no change in the course of 
DTI-metrics over time in the defined groups (all patients without new 
ON, NMO-ON and NMO-NON; data not shown). 
3.3.2. New ON during follow-up: a case series of four patients 
Four patients suffered new ON episodes during follow-up, all of 
whom already had ON episodes prior to baseline (NMO-ON). The new 
ON episodes were unilateral for three patients (n = 2 on the right and n 
= 1 on the left eye), while one patient (P4) suffered one episode of 
bilateral ON and an additional episode of left ON one month later. 
The total LGN volumes of these four patients at different visits are 
shown in Table 4 and Fig. 4. 
There was no difference in total LGN volume between V1 (median 
time since new ON: 1.3 years with range 1.0 to 2.6) and V0 (t = 2.0, p =
0.144, mean difference: 10.3 mm3, with 95% CI: − 6.4 to 27.0). How-
ever, at Vlast (median time since new ON: 2.6 years with range: 1.8 to 
Fig. 3. Course of total LGN volume during the study in different groups/sub-
groups. Legend: There was no significant change in total LGN volume during 
follow-up in any groups (HC, all patients, NMO-ON, NMO-NON). Moreover, 
there was no group effect on LGN volume change: A) neither between HC and 
all AQP4-IgG seropositive NMOSD patients; B) nor between NMO-NON and 
NMO-ON patients. Note that the y axis represents the change in total LGN 
volume (sum of right and left) and not the absolute volumes. Moreover, note 
that there were only 9 HC with 2- and 3 HC with 3 years follow-up, which at 
least partly explains the higher variance in LGN volume change seen in HC, as 
shown in A. Abbreviations: HC = healthy controls, LGN = lateral geniculate 
nucleus, NMO-NON: patients with NMOSD and no prior optic neuritis, NMO- 
ON: patients with NMOSD and prior optic neuritis, SE = standard error. 
Table 4 
Course of total LGN volume in four patients with new ON during follow-up and 
in four “control”-patients.  
4i) Patients with new  
ON during follow-up 
Total LGN volume (sum of right and left), mm3  
(time since new ON, y) 
V0 V1 Vlast 
P1 327.4 (− 0.8y) 332.0 (+1.8y) 310.6 (+3.9y) 
P2 451.0 (− 0.4y) 451.3 (+0.9y) 422.5 (+2.8y) 
P3 367.5 (− 0.2y) 391.8 (+0.8y) 362.2 (+1.8y) 
P4 338.5 (− 1.1y) 350.4 (+0.2y) 312.7 (+2.3y) 
Mean ± SD of P1-P4 371.1 ± 55.9 * 381.4 ± 52.9 352 ± 52.7 *  
4ii) Four matched “negative  
controls”-patients without  
new ON during follow-up 
Total LGN volume (sum of right and left), mm3 
V0 V1 Vlast 
CP1 442.7 431.7 415.5 
CP2 420.4 405.1 419.9 
CP3 331.5 329.0 340.2 
CP4 385.2 421.2 405.4 
Mean ± SD of CP1-CP4 394.9 ± 48.5 396.8 ± 46.5 395.2 ± 37.2 
For the patients with new ON during follow-up, V0 was the last visit before the 
new ON episode, while V1, and Vlast were visits after the new ON episode. For 
the matched patients without new ON during follow-up, V0 was the baseline 
visit and Vlast the last available visit. Note that P3 had only a total of two visits 
after the new ON episode, thus V2 is at the same time the last available visit 
(Vlast). Similarly, for CP3 V2 is at the same time Vlast. In patients with new ON, 
the difference between Vlast and V0 was significant (p = 0.036), while there was 
no difference between V1 and V0. In four patients without new ON that were as 
well matched as possible to the four patients with new ON, there were no dif-
ferences in total LGN volume between visits. 
Abbreviations: LGN = lateral geniculate nucleus, ON = optic neuritis, SD =
standard deviation. 
Fig. 4. LGN volume course in four patients with new ON during follow-up 
Legend: V0 is for all patients the last visit before the new ON episode and 
Vlast the last available visit. The time of new ON episodes is indicated with the 
red arrows. Note that patients P1-P3 had only one new ON episode, while P4 
had two new episodes, with one month interval inbetween. In a paired t-test, 
mean LGN volume (sum of both hemispehres) was reduced in these four pa-
tients at Vlast compared to V0 (see also Table 4). Abbreviations: LNG = lateral 
geniculate nucleus, ON = optic neuritis. (For interpretation of the references to 
colour in this figure legend, the reader is referred to the web version of 
this article.) 
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3.9 years) we found a significant decrease in total LGN volume 
compared to V0 (t = − 3.6, p = 0.036, mean difference: − 19.1, with 95% 
CI: − 35.8 to − 2.4) (Table 4i). This volume change was specific for the 
LGN, since the total thalamic volume did not differ between Vlast and V0 
(t = 0.4, p = 0.713, mean difference: 43.9, with 95% CI: − 302.1 to 
390.1). 
For comparison, we examined the course of total LGN volume in four 
patients that did not show new ON episodes during follow-up (“negative 
controls”). We chose these patients -blinded to their LGN volumes- to be 
as well matched as possible to the four patients with new ON (for details 
see also Table S1). In this analysis, we did not find any change in total 
LGN volume between V1 and V0 (t = − 0.2, p = 0.887, mean difference: 
− 1.8, with 95% CI − 39.1 to 35.4), nor between Vlast and V0 (median 
follow-up: 4.1 years with range 3.4 to 4.2; t = − 0.03, p = 0.979, mean 
difference: − 0.29, with 95% CI –32.5 to 31.9) (Table 4ii). 
4. Discussion 
In the current study, we examined longitudinal quantitative changes 
in the LGN of patients with AQP4-IgG seropositive NMOSD. Our cross- 
sectional findings at baseline, with reduced LGN volumes in NMO-ON 
patients, are in line with two previous studies, one from our own 
group (Papadopoulou et al., 2019; Tian et al., 2018). Here, we addi-
tionally observed significant cross-sectional associations between the 
LGN volume and other measures of structural damage along the visual 
pathway: i) neuroaxonal loss in the retina, as measured by OCT, and ii) 
microstructural damage in the OR, as measured by DTI. Most of these 
associations remained significant only in the NMO-ON-subgroup, sug-
gesting that they were driven by prior ON. In line with this, we observed 
a reduction in total LGN volume of four patients showing new ON during 
follow-up. Overall, these results support the occurrence of anterograde 
trans-synaptic degeneration after ON in AQP4-IgG seropositive NMOSD. 
Moreover, our findings underline the role of LGN volume as a marker 
of ON-related damage in the afferent visual pathway of these patients, 
which is also associated with visual function, according to our previous 
study (Papadopoulou et al., 2019). LGN volume as marker also has the 
advantage of its utility with a widely available MRI sequence 
(MPRAGE). The latter is relevant, since other measures of structural 
damage in the visual pathway (pRNFL- and GCIPl-thickness, mean FA 
and MD of the OR) require either OCT- or DTI, which are often not 
available in regular clinical practice (Papadopoulou et al., 2019). 
In contrast to the above-mentioned results, we did not find pro-
gressive LGN volume loss in patients that did not suffer new ON episodes 
during follow-up. Although our small sample size may limit the gener-
alizability of our results, this argues against occult neurodegenerative 
damage along the visual pathway in AQP4-IgG seropositive NMOSD, 
which is also suggested by the normal baseline LGN volumes of NMO- 
NON patients. 
Although longitudinal MRI data in NMOSD are very limited, the 
absence of progressive neurodegeneration over time is in line with 
previous findings. One study with 18 AQP4-IgG-seropositive NMOSD 
patients and 15 patients with relapsing-remitting (RR)MS examined 
changes in volumetric and microstructural brain measures over time 
(Matthews et al., 2015). Overall, NMOSD patients did not show any 
changes over one-year follow-up (no reduction in brain and thalamic 
volume, no changes in the FA of normal appearing white matter, or the 
myelin water imaging of the brain). This was in contrast to the changes 
observed in the MS group, including a decrease in thalamic volume and 
FA reduction in multiple white matter regions (Matthews et al., 2015). A 
subgroup of patients in this previous study also underwent myelin-water 
imaging of their cervical spinal cord (Combes et al., 2017), which 
showed reduced myelin water fraction in lesional and non-lesional 
cervical cord areas of NMOSD patients at baseline, but no changes 
over one year follow-up, in contrast to MS patients, which showed a 
decrease (Combes et al., 2017). 
This previous study highlights the differences between AQP4-IgG- 
seropositive NMOSD and MS regarding the mechanisms of neuro-
degeneration. On one hand, attack-related remote neurodegeneration, 
as in anterograde trans-synaptic degeneration after optic neuritis, seems 
to occur both in NMO-ON (Papadopoulou et al., 2019; Tian et al., 2018; 
Pichiecchio et al., 2012; Manogaran et al., 2016; Oertel et al., 2017) and 
in MS (Papadopoulou et al., 2019; Balk et al., 2015; Gabilondo et al., 
2014; Ciccarelli et al., 2005; Audoin et al., 2006; Rocca et al., 2013). On 
the other hand, subclinical ongoing neurodegeneration independently of 
attacks and/or lesions is probably a hallmark of MS and not AQP4-IgG- 
seropositive NMOSD. Several studies have shown progressive neuro-
degeneration measured as grey matter atrophy in patients with MS, 
which is at least partially independent of focal lesions (Calabrese et al., 
2015). Although its mechanisms are still not completely understood and 
probably combine both degenerative (e.g. neuroaxonal damage due to 
mitochondrial dysfunction) and inflammatory pathways (Calabrese 
et al., 2015); grey matter damage in MS is believed to be strongly 
associated to progression (Stadelmann, 2011). Thus, the lack of pro-
gressive deep grey matter damage in AQP4-IgG-seropositive NMOSD 
suggested by our current and previous findings (normal volumes of deep 
grey matter structures (Finke et al., 2016) and of other thalamic nuclei 
than the LGN (Papadopoulou et al., 2019) would be in line with the 
clinical observation, that progression in NMOSD is extremely rare 
(Wingerchuk et al., 2007). 
However, there are also some contradictory findings regarding sub-
clinical neuroaxonal damage in NMOSD. For example, previous studies 
-also from our group- showed reduced GCIPL volumes (Oertel et al., 
2018) and microstructural OR changes (Oertel et al., 2017) in AQP4-IgG 
seropositive NMOSD, even without prior ON. Moreover, a longitudinal 
analysis of OCT-data in these patients (Oertel et al., 2018) revealed 
GCIPL loss over time, without new ON attacks. The reasons for this 
discrepancy are not clear. It could be that neurodegenerative processes 
are different in the brain vs. retina in NMOSD, with a primary retinop-
athy being potentially responsible for occult GCIPL loss. Moreover, 
retrograde degeneration due to contralateral ON with chiasmal affection 
could play a role in the GCIPL loss of non-ON eyes (Oertel et al., 2018), 
since in this previous study non-affected eyes of patients with unilateral 
ON were included. 
Last, it cannot be ruled out that we had insufficient power to detect 
subtle subclinical volume loss at the LGN level in the current longitu-
dinal analysis. This might be due to the relatively low number of patients 
included in the study, particularly in the NMO-NON subgroup (n = 12). 
In this regard, there is need for larger studies, and at the same time, 
for robust MRI-markers reflecting structural damage in the visual 
pathway of patients with NMOSD. The LGN volume might be such a 
marker. Most previous studies assessing LGN volume in healthy volun-
teers (Fujita et al., 2001; Kitajima et al., 2015), patients with glaucoma 
(Dai et al., 2011; Chen et al., 2013; Furlanetto et al., 2018) and patients 
with NMOSD (Tian et al., 2018) used manual segmentation, which is 
time-consuming and probably inacurate for such a small grey matter 
structure (Magon et al., 2014). In our current and previous NMOSD- 
study (Papadopoulou et al., 2019), the LGN volume was measured 
using an atlas-based tool of automated segmentation of the thalamic 
nuclei, the MAGeT Brain algorithm (Chakravarty et al., 2006). MAGeT 
was validated against manual segmentations (Chakravarty et al., 2009), 
intraoperative recordings (Chakravarty et al., 2008) and functional MRI 
(Chakravarty et al., 2009). It was previously used to show LGN volume 
loss in patients with MS compared to controls (Papadopoulou et al., 
2019). It has the advantages of automated vs. manual segmentation 
regarding rapidity and reliability, with also reduction of random errors. 
The latter is achieved by using a representative subgroup of the study 
population to create a template library and generate multiple segmen-
tations of all other MRIs. This approach may be also useful to address the 
potential limitation of MAGeT in a longitudinal analysis, relating to the 
variability across MRI scans due to physiological or methodological 
factors. This limitation might be particularly problematic in the analysis 
of small structures like the LGN. The use of the template library, where 
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MRI sessions are sampled from all timepoints to be representative of 
possible changes over time additionally to demographic and clinical 
characteristics of the study population, should reduce this bias (Magon 
et al., 2020). A previous longitudinal analysis using MAGeT in MS 
showed correlations between volume loss of multiple thalamic nuclei 
(including the LGN) with the EDSS and -for three nuclei- with EDSS 
change over time. The latter was shown for example for the anterior 
nucleus, which had a similar volume to the LGN (Magon et al., 2020), 
suggesting that MAGeT can measure clinically meaningful changes over 
time even in small nuclei. However, it must be noted that -when looking 
at single patients- there is a considerable measurement variability in 
total LGN volume among different visits, which is restrictive in the use of 
this MRI marker at an individual level. In line with this, as also seen in 
the group of HC in the current study (see Fig. 3), the variability in the 
LGN volume measurement increases in small groups, which is an addi-
tional methodological limitation especially for small cohorts, as also in 
the current study. Thus, it is possible that the lack of LGN volume loss 
over time in the current study may be due to its relatively low power, 
since subtle volume changes may remain undetected in an analysis with 
small sample size and thus large measurement variability. 
The main limitation of our study is indeed the relatively small 
number of patients. The sample size was particularly small in the sub-
group of patients with new ON during follow-up (n = 4). Given the 
currently low annual relapse rates under immunosuppressive therapy, 
larger-potentially multicenter-studies are needed to further examine and 
confirm the temporal evolution of LGN volume after a (new) ON attack 
and its potential relevance for visual function. In this regard, it would be 
also interesting to investigate whether the small volume increase we 
observed at visit 1 after new ON (n.s.) is indeed a real phenomenon, or 
only artefact due to our small number of patients with new ON. 
On the other hand, the inclusion of a well characterized cohort of 
AQP4-IgG seropositive NMOSD patients and the longitudinal analysis 
are strengths of this study. Moreover, we combined several methods for 
a comprehensive structural assessment of the afferent visual pathway: 
OCT for the retinal neuroaxonal integrity, DTI for the OR-microstructure 
and MAGeT for the LGN (Chakravarty et al., 2013). Through this com-
bination we could show that LGN is not only smaller in NMO-ON, but 
also associated both with the retina- and OR-measures, confirming a 
cascade of damage along different parts of the visual pathway that are 
anatomically connected. 
5. Conclusions 
To conclude, despite reduced LGN volume in NMO-ON patients at 
baseline, we did not find subsequent LGN atrophy in the absence of new 
ON episodes. This suggests that LGN atrophy due to trans-synaptic 
degeneration in NMOSD occurs after ON but is not progressive over 
long-term follow-up, or independent of ON attacks. Our findings favour 
ON attack-related rather than occult neurodegenerative processes in 
AQP4-IgG seropositive NMOSD. Moreover, they underline the role of 
LGN volume as a marker of ON-associated structural damage, with the 
advantage of automated measurement on widely available MRI 
sequences. 
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